Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cerevance
Biotech
Cerevance fails phase 2 trial in early, untreated Parkinson's
Solengepras performed no better than placebo in phase 2 when given as a monotherapy to people with early, untreated Parkinson’s.
Nick Paul Taylor
Apr 1, 2025 10:19am
CRISPR-focused Caribou christens new CMO—Chutes & Ladders
Aug 16, 2024 8:30am
3 Flagship biotechs make key exec hires—Chutes & Ladders
Aug 18, 2023 9:30am
Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact
Aug 9, 2022 10:00am
Gates, GV chip into $45M round for CNS biotech Cerevance
Apr 14, 2020 7:00am
Takeda taps brain-focused Cerevance in quest for new GI targets
Dec 17, 2019 5:36pm
